MA28396B1 - Dérivés de quinoléine nouveaux - Google Patents

Dérivés de quinoléine nouveaux

Info

Publication number
MA28396B1
MA28396B1 MA29132A MA29132A MA28396B1 MA 28396 B1 MA28396 B1 MA 28396B1 MA 29132 A MA29132 A MA 29132A MA 29132 A MA29132 A MA 29132A MA 28396 B1 MA28396 B1 MA 28396B1
Authority
MA
Morocco
Prior art keywords
quinoline derivatives
new quinoline
new
derivatives
quinoline
Prior art date
Application number
MA29132A
Other languages
English (en)
Inventor
Yufeng Hong
Robert Steven Kania
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28396(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA28396B1 publication Critical patent/MA28396B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29132A 2003-12-23 2006-06-23 Dérivés de quinoléine nouveaux MA28396B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53272503P 2003-12-23 2003-12-23

Publications (1)

Publication Number Publication Date
MA28396B1 true MA28396B1 (fr) 2007-01-02

Family

ID=34738830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29132A MA28396B1 (fr) 2003-12-23 2006-06-23 Dérivés de quinoléine nouveaux

Country Status (33)

Country Link
US (2) US7381824B2 (fr)
EP (1) EP1699780A1 (fr)
JP (1) JP4503022B2 (fr)
KR (1) KR100807920B1 (fr)
CN (1) CN1890234A (fr)
AP (1) AP2006003619A0 (fr)
AR (1) AR048292A1 (fr)
AU (1) AU2004309166B2 (fr)
BR (1) BRPI0418102A (fr)
CA (1) CA2551508C (fr)
CR (1) CR8482A (fr)
EA (1) EA009994B1 (fr)
EC (1) ECSP066671A (fr)
GE (1) GEP20084572B (fr)
GT (1) GT200400274A (fr)
HN (1) HN2004000544A (fr)
IL (1) IL175947A (fr)
IS (1) IS8439A (fr)
MA (1) MA28396B1 (fr)
MX (1) MXPA06007242A (fr)
MY (1) MY139446A (fr)
NL (1) NL1027847C2 (fr)
NO (1) NO20063382L (fr)
NZ (1) NZ547009A (fr)
OA (1) OA13349A (fr)
PE (1) PE20050757A1 (fr)
SG (1) SG141459A1 (fr)
TN (1) TNSN06200A1 (fr)
TW (1) TWI331148B (fr)
UA (1) UA82577C2 (fr)
UY (1) UY28692A1 (fr)
WO (1) WO2005063739A1 (fr)
ZA (1) ZA200603657B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009994B1 (ru) * 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные
WO2005073224A2 (fr) * 2004-01-23 2005-08-11 Amgen Inc Composes et methodes d'utilisation de ces derniers
MX2008001838A (es) 2005-08-08 2008-04-09 Pfizer Sales y polimorfos de un inhibidor de vegf-r.
CA2632384A1 (fr) * 2005-12-05 2007-06-14 Pfizer Products Inc. Procedes de preparation d'un inhibiteur du vegf-r
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008020302A2 (fr) * 2006-08-17 2008-02-21 Pfizer Products Inc. Composés hétéro-aromatiques à base de quinoline
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
NZ580671A (en) 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2340244A4 (fr) * 2008-10-14 2012-07-25 Ning Xi Composés et procédés d'utilisation
IT1393351B1 (it) * 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
ES2578990T3 (es) * 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
EP2496578A4 (fr) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
FR2973703A1 (fr) * 2011-04-08 2012-10-12 Univ Provence Aix Marseille 1 Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN103524409B (zh) * 2013-09-26 2015-09-02 上海仁力医药科技有限公司 喹啉类化合物及其制备方法与应用
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP2974729A1 (fr) * 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
WO2016161952A1 (fr) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
WO2018059534A1 (fr) * 2016-09-30 2018-04-05 广东众生药业股份有限公司 Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase
CN107337634B (zh) * 2017-08-28 2019-07-09 新发药业有限公司 一种阿贝西利中间体化合物的制备方法
FR3080620B1 (fr) 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
AU2020271855B2 (en) * 2019-04-12 2025-11-27 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
TW202340164A (zh) * 2022-01-21 2023-10-16 大陸商深圳默元生物科技有限公司 Ｎ－羥基喹啉甲醯胺化合物及其用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (fr) * 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
JPS62168137A (ja) * 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (fr) 1991-05-29 1994-03-16 Pfizer Inc. Composes tricycliques polyhydroxyliques inhibiteurs de la tyrosine-kinase
FI940469L (fi) 1991-08-02 1994-02-01 Pfizer Kinoliinijohdannaisia immunostimulantteina
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
BR9506936A (pt) 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (fr) 1994-11-12 1997-12-01 Zeneca Ltd
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
ATE247469T1 (de) 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
EP0907642B1 (fr) 1996-06-24 2005-11-02 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
US6071935A (en) * 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
KR100567649B1 (ko) * 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
PL335235A1 (en) 1997-02-19 2000-04-10 Berlex Lab N-heterocyclic derivatives as nos inhibitors
EP0984930B1 (fr) 1997-05-07 2005-04-06 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
EP0980258A1 (fr) 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
CA2291709A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
WO1999010349A1 (fr) 1997-08-22 1999-03-04 Zeneca Limited Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
CA2309690A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
CA2328893A1 (fr) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
BR9914167B1 (pt) * 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
IL144461A0 (en) * 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
AU2223501A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
EP1243582A4 (fr) 1999-12-24 2003-06-04 Kirin Brewery Quinoline, derives de la quinazoline et medicaments contenant ces substances
EP1265635A1 (fr) 2000-03-22 2002-12-18 Glaxo Group Limited Produit pharmaceutique comprenant un agent bloquant le cycle cellulaire et anticorps
RU2002129574A (ru) 2000-03-31 2004-04-20 Имклон Системс Инкорпорейтед (Us) Лечение неплотных опухолей молочной железы антагонистами рецепторов сосудистого эндотелиального фактора роста
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2407858C (fr) 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation d'inhibiteurs du facteur de croissance placentaire pour le traitement de l'angiogenese pathologique, de l'arteriogenese pathologique, de l'inflammation, de la formation tumorale et/ou de la fuite vasculaire
WO2002012226A1 (fr) * 2000-08-09 2002-02-14 Astrazeneca Ab Derives de la quinoline presentant une activite inhibant le facteur de croissance vegf
KR100389127B1 (ko) 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
AU2001296821A1 (en) 2000-10-12 2002-04-22 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
ATE369894T1 (de) 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
WO2002064170A1 (fr) 2001-02-09 2002-08-22 Children's Medical Center Corporation Methode pour traiter le cancer et augmenter le taux d'hematocrite
WO2003006059A1 (fr) 2001-07-13 2003-01-23 Imclone Systems Incorporated Anticorps diriges contre vegfr-1 pour traiter le cancer du sein
EP1447405A4 (fr) 2001-10-17 2005-01-12 Kirin Brewery Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
IL161462A0 (en) 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
BR0308162A (pt) * 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
EP1548008A4 (fr) 2002-08-23 2008-08-06 Kirin Pharma Kk Compose presentant une activite inhibitrice du facteur de croissance transformant beta et composition medicamenteuse en contenant
WO2004020434A1 (fr) 2002-08-30 2004-03-11 Eisai Co., Ltd. Derives d'azaarene
EA009994B1 (ru) * 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные

Also Published As

Publication number Publication date
US7923457B2 (en) 2011-04-12
TW200526218A (en) 2005-08-16
AR048292A1 (es) 2006-04-19
US20050137395A1 (en) 2005-06-23
UY28692A1 (es) 2005-07-29
MXPA06007242A (es) 2006-08-18
CA2551508A1 (fr) 2005-07-14
HN2004000544A (es) 2010-06-09
IL175947A0 (en) 2006-10-05
KR100807920B1 (ko) 2008-02-27
CN1890234A (zh) 2007-01-03
US20090069316A1 (en) 2009-03-12
GT200400274A (es) 2005-09-20
US7381824B2 (en) 2008-06-03
OA13349A (en) 2007-04-13
AU2004309166A1 (en) 2005-07-14
NL1027847C2 (nl) 2006-04-19
NL1027847A1 (nl) 2005-06-27
IS8439A (is) 2006-05-04
BRPI0418102A (pt) 2007-04-27
IL175947A (en) 2012-08-30
CA2551508C (fr) 2011-08-09
KR20060101548A (ko) 2006-09-25
JP4503022B2 (ja) 2010-07-14
ZA200603657B (en) 2007-08-29
UA82577C2 (en) 2008-04-25
EP1699780A1 (fr) 2006-09-13
AP2006003619A0 (en) 2006-06-30
EA009994B1 (ru) 2008-06-30
CR8482A (es) 2007-12-17
MY139446A (en) 2009-10-30
TNSN06200A1 (fr) 2007-11-15
ECSP066671A (es) 2006-10-25
JP2007516273A (ja) 2007-06-21
GEP20084572B (en) 2008-12-25
NO20063382L (no) 2006-09-20
WO2005063739A1 (fr) 2005-07-14
TWI331148B (en) 2010-10-01
SG141459A1 (en) 2008-04-28
NZ547009A (en) 2009-09-25
EA200600892A1 (ru) 2006-12-29
AU2004309166B2 (en) 2008-02-21
PE20050757A1 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
MA28396B1 (fr) Dérivés de quinoléine nouveaux
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE352550T1 (de) Chinazolinderivate
MA28347A1 (fr) Dérivés de quinoléine substitués
ATE420066T1 (de) Amidoacetonitrilderivate
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE499347T1 (de) Amidderivate
MA28816B1 (fr) Nouveaux derives de 4-benzylidene-piperidine
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS2656B (is) Nýjar besímídasólafleiður
EP1630162A4 (fr) Derive de 2-aminoquinoline
DK1652843T3 (da) Amidderivater
EP1643987A4 (fr) Derives de podophyllotoxine
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
ATE449064T1 (de) Amidoacetonitrilderivate
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
IS8195A (is) Ásetnar pýrrólafleiður
IS8045A (is) Púrín-6-ón-afleiður
DK1633719T3 (da) Substituerede spirobenzazepiner
ATE460391T1 (de) 2-aminobenzoylderivate
IS7924A (is) Setnar anilín afleiður
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
EP1697515A4 (fr) Conjugue adn-excipient
UY28661A1 (es) Derivados de cromano